True vasculitis in lupus nephritis

Clinical Nephrology

Volumn 74, Issue 2, 2010, Pages 106-112

  Abdellatif, A A ^a   Waris, S ^a   Lakhani, A ^a   Kadikoy, H ^a   Haque, W ^a   Truong, L D ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Lupus nephritis; Lupus vasculitis; Lupus vasculopathy; Rituximab; Systemic lupus erythematosus; True renal vasculitis; Vasculitis

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ARTERIOSCLEROSIS; ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; RENOVASCULAR DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; COMPLICATION; DISEASE COURSE; IMMUNOLOGY; PATHOLOGY;

ANTI-ENDOTHELIAL CELL ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LUPUS NEPHRITIS; VASCULITIS;

EID: 77955726519     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74106     Document Type: Article

References (39)

1. Cameron JS. Lupus nephritis: an historical perspective 1968-1998. J Nephrol. 1999; 12: 29-41.
2. Koch M, Beckmann R. Transitory lupus anticoagulant antibodies leading to a quickly resolvable left ventricular thrombus in a young female patient on peritoneal dialysis due to terminal renal failure. Clin Nephrol. 2009; 71: 575-578.
3. Omokawa, Wakui H, Okuyama S, Togashi M, Ohtani H, Komatsuda A, Ichinohasama R, Sawada K. Predominant tubulointerstitial nephritis in a patient with systemic lupus erythematosus: phenotype of infiltrating cells. Clin Nephrol. 2008; 69: 436-444. (Pubitemid 351803485)
4. Appel GB, Pirani C, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994; 4: 1499-1515.
5. Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, Sacchi G. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Am J Kidney Dis. 1991; 18: 240-248.
6. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zeron P, Bove A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006; 85: 95-104.
7. Goel D, Reddy SR, Sundaram C, Prayaga AK, Rajasekhar L, Narsimulu G. Active necrotizing cerebral vasculitis in systemic lupus erythematosus. Neuropathology. 2007; 27: 561-565. (Pubitemid 350045674)
8. Descombes E, Droz D, Drouet L, Grünfeld JP, Lesavre P. Renal vascular lesions in lupus nephritis. Medicine (Baltimore). 1997; 76: 355-368. (Pubitemid 27451327)
9. Schwartz MM, Lan SP, Bonsib SM, Gephardt GM, Sharma HM. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis. 1989; 13: 273-283.
10. Feriozzi S, Muda AO, Amini M, Faraggiana T, Ancarani E. Systemic lupus erythematosus with membranous glomerulonephritis and uterine vasculitis. Am J Kidney Dis. 1997; 29: 277-279. (Pubitemid 27130740)
11. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant. 1998; 13: 2821-2824. (Pubitemid 28479528)
12. Pradhan VD, Badakere SS, Bichile LS, Almeida AF. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J Assoc Physicians India. 2004; 52: 533-537.
13. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003; 12: 651-658. (Pubitemid 37173660)
14. Pan HF, Fang XH, Wu GC, Li WX, Zhao XF, Li XP, Xu JH, Ye DQ. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation. 2008; 31: 260-265.
15. Tan E M, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
16. Moeckel GW, Jabs K, Fogo AB. An 11-year-old african-american girl with systemic lupus erythematosus and ANCA-negative renal vasculitis. Am J Kidney Dis. 2002; 39: 433-438. (Pubitemid 34174271)
17. Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies againstmicrovascular and macrovascular endothelial cells. Arthritis Rheum. 2001; 44: 1484-1494.
18. Renaudineau Y, Dugue C, Dueymes M. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev. 2002; 1: 365-372. (Pubitemid 38340250)
19. Cieslik P, Hrycek A, Klucinski P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol Arch Med Wewn. 2008; 118: 57-63. (Pubitemid 351316529)
20. Del Papa N, Raschi E, Moroni G, Panzeri P, Borghi MO, Ponticelli C, Tincani A, Balestrieri G, Meroni PL. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus. 1999; 8: 423-429. (Pubitemid 29423575)
21. Schwartz MM. The pathology of lupus nephritis. Semin Nephrol. 2007; 27: 22-34.
22. D'Cruz D. Vasculitis in systemic lupus erythematosus. Lupus. 1998; 7: 270-274.
23. Kallenberg CGM, Heeringa P. Pathogenesis of vasculitis. Lupus. 1998; 7: 280-284.
24. Tsumagari T, Fukumoto S, Kinjo M, Tanaka K. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol. 1985 ; 16: 43-49. (Pubitemid 15158748)
25. Bhuyan UN, Malaviya AN, Dash SC, Malhotra KK. Prognostic significance of renal angiitis in systemic lupus erythematosus (SLE). Clin Nephrol. 1983; 20: 109-113. (Pubitemid 13050293)
26. Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: Light and immunofluorescence microscopic observations. Am J Kidney Dis. 1982; 2: 135-141. (Pubitemid 13230785)
27. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006; 70: 1403-1412.
28. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008; 17: 426-430.
29. Ibernon M, Poveda R, Vidaller A, Bestard O, Grinyó JM. Mycophenolate mofetil in anti MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity. Clin Nephrol. 2008; 69: 395-401. (Pubitemid 351803479)
30. Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 2007; 72: 676-682. (Pubitemid 47373785)
31. Kusaba T, Hatta T, Tanda S, Kameyama H, Tamagaki K, Okigaki M, Inaba T, Shimazaki C, Sasaki S. Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab. Clin Nephrol. 2006; 65: 222-226. (Pubitemid 43338003)
32. Cobo M, Hernández D, Rodriguez C, Pérez-Tamajón L. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis. Clin Nephrol. 2006; 66: 54-57. (Pubitemid 44043733)
33. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi T, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. Successful therapeutic use of a single dose of rituximab on relapse in the adults with minimal change nephrotic syndrome. Clin Nephrol. 2009; 72: 69-72.
34. Kadikoy H, Haque W, Ahmed S, Abdellatif A. Rituximab in the treatment of refractory lupus nephritis with vasculitis. S J Kidney Dis Transpl [Accepted].
35. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52: 501-513. (Pubitemid 40216314)
36. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud- Mendoza C, Gonzalez-Amaro R. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006; 8: R83.
37. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005; 64: 913-920. (Pubitemid 40733918)
38. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody positive vasculitis successfully treated with rituximab. J Internal Med. 2005; 257: 540-548. (Pubitemid 40776514)
39. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, Noël LH, Fakhouri F. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009; 4: 579-587.